Drug intelligence / Profile preview

AMX-00x

Development stage: Preclinical
Lead developer: Amyl Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AMX-00x is a preclinical-stage monoclonal antibody being developed by Amyl Therapeutics. It is designed as a pan-amyloid immunotherapy that targets aggregated species of both alpha-synuclein and tau. This dual-targeting approach aims to address the protein misfolding and aggregation characteristic of Parkinson's disease and potentially other neurodegenerative disorders. By binding to these toxic aggregates, AMX-00x seeks to clear them from the brain and prevent further neurodegeneration.

Targets

MAPT (Microtubule-associated protein tau)SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on AMX-00x.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMX-00x.

Explore the full profile